Clinical trial
A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adult Patients With Relapsed/Refractory DLBCL and iNHL Who Are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (ASCT)
NCT05265975 is registered in ClinicalTrials.gov with Antengene Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adult Patients With Relapsed/Refractory DLBCL and iNHL Who Are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (ASCT)
- Lead sponsor
- Antengene Corporation
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- April 7, 2022
- Completion date
- December 31, 2024
- Enrollment
- 54 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b-cell lymphoma, indolent non-hodgkin lymphoma